This inventor holds 14 USPTO granted patents and 9 published patent applications, plus 1 CIPO patent and 4 EPO patents. Top assignees: 4D Molecular Therapeutics Inc., 4 Molecular Therapeutics Inc., Ad Molecular Therapeutics Inc.. Active years: 2021-2025.
Company Filing History:
11 out of 15 
1 out of 1 
1 out of 1 Years Active: 2021-2025
Title: David Schaffer – Innovator in Gene Therapy
Introduction
David Schaffer is a prominent inventor based in Emeryville, California, with an impressive portfolio of 14 patents. His work primarily focuses on advancements in gene therapy, particularly through the development of adeno-associated virus (AAV) variant capsid proteins. These innovations have potential applications in treating muscle disorders, marking significant strides in medical research and clinical practices.
Latest Patents
Among David Schaffer’s notable contributions is his recent patent for “Adeno-associated virus variant capsids and methods of use thereof.” This invention details variant AAV capsid proteins that have been modified to enhance the infectivity of specific muscle cells. These advancements provide a foundation for the creation of recombinant AAV virions and pharmaceutical compositions that can effectively deliver nucleic acid sequences for therapeutic uses. Such innovative methods promise to revolutionize treatment options for various muscle diseases, showcasing the potential of gene therapy in medicine.
Career Highlights
David Schaffer has had a significant impact on the field of gene therapy through his work with 4D Molecular Therapeutics and 4 Molecular Therapeutics. His expertise has been instrumental in pioneering technologies that support the application of AAVs in therapeutic settings, enabling researchers to push the boundaries of what is possible in gene delivery systems.
Collaborations
Throughout his career, Schaffer has collaborated with esteemed colleagues such as David H Kirn and Melissa Kotterman. These partnerships have fostered a collaborative environment that enhances innovation and drives forward the development of new therapeutic approaches in gene therapy.
Conclusion
David Schaffer exemplifies the spirit of innovation in the realm of gene therapy through his extensive patent portfolio and collaborative efforts. His contributions are not only significant for their scientific merit but also for their potential to transform treatment strategies for muscle disorders. As the field continues to evolve, Schaffer’s work will undoubtedly leave an enduring legacy in the medical research community.